Hormone Therapy Linked to How Some Women Respond to GLP-1 Weight Loss Drugs
Summary
A retrospective study of women aged 45 and older found that those taking menopause hormone therapy lost somewhat more weight while using semaglutide than women not taking hormone therapy. Differences among tirzepatide users were smaller and were not statistically significant at later follow-ups. Researchers cautioned that the study cannot establish cause and effect, and hormone therapy is not recommended solely for weight loss.Key Facts
- The study used electronic health records for women with overweight or obesity who were prescribed semaglutide or tirzepatide.
- The semaglutide group included 2,379 women, and the tirzepatide group included 1,476.
- After 15 months, semaglutide users taking hormone therapy had lost an average of 11.6 percent of their body weight, compared with 9.7 percent among those not taking it.
- At final follow-up, average weight loss among semaglutide users was 11.9 percent for hormone therapy users and 10.9 percent for nonusers.
- Among semaglutide users, 55 percent of hormone therapy users lost at least 10 percent of their body weight, compared with 51 percent of nonusers.
- For tirzepatide users, hormone therapy was linked to slightly greater weight loss in the first three months, but later differences were not statistically significant.
- The study was observational and was not designed to compare semaglutide directly with tirzepatide.
- The lead author said menopause hormone therapy should not be used solely to promote weight loss.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
